The Biological Resources Branch (BRB) is one of the extramural arms of the Developmental Therapeutics Program (DTP), NCI. The BRB supports preclinical and early (e.g. Phase I) clinical studies of biological response modifiers (BRMs) research in the biomedical community through a program of grants and contracts. These studies assess the effects of novel biological agents and explore relationships of biological responses with antitumor activity. The NCI Preclinical Repository distributes selected agents for peer-reviewed preclinical studies performed by both extramural and intramural investigators. Other contracts support the production and in vivo evaluation, both clinical and non-clinical, of biologicals including monoclonal antibodies, recombinant proteins, nucleic acids, viral vectors, whole-cell therapeutics, and natural products.
The NCI BRB Program Staff provide oversight of the Biopharmaceutical Development Program (BDP) at the National Cancer Institute Frederick campus (NCI-Frederick). The BDP produces a variety of biopharmaceuticals under current Good Manufacturing Practices (cGMP) for Phase I/II human clinical trials or advanced preclinical animal testing. The BDP is operated under contract by Scientific Applications International Corporation (SAIC) Frederick, which provides operations and technical support to the FCRDC.
|
|||||
|
|
|
|
|
|
| Privacy and Disclaimer | |||||
